Preface

The U.S. BioPharma sector encompasses biotechnology and pharmaceutical companies and is one of the most complex and dynamic sectors in the healthcare industry. The BioPharma sector has been on the forefront globally in offering innovative and highly effective medications to patients, mainly because of its great appetite to find cures, encouragement of fundamental research, aggressive investments into risky research and development ventures combined with relatively attractive market economics and supporting policy environment. The life-saving and life-enhancing medicines that BioPharma companies produce have a profound impact on the society in terms of enhancing quality of life, increasing productivity, and decreasing burden of disease.

The pharmaceutical sector which has economically thrived for several decades has transformed into BioPharmaceutical sector with technological breakthroughs on the biotech front. Lately, the BioPharma sector has been at an inflexion point as both the economics and healthcare environment are getting increasingly challenging here in the U.S. and elsewhere. Currently, discovering and developing drugs require significant investments and is a process that is arduous with low success rates. The success of this sector boils down to its continued ability to come up with innovate new medicines and being able to aggressively commercialize them in the U.S. and elsewhere to maximize the return on investments.

The complexity in drug development is fairly evident as most early stage products fail to reach the market, billion dollar late stage development projects are getting shut down due to unexpected safety challenges, and the ones that make it through often are failing to obtain FDA approval. Even those that get FDA approval are facing an uphill battle to attain commercial success especially if the product value proposition is not attractive for the stakeholders to adopt the product. Hence, it is needless to mention that any BioPharma investor must understand these nuisances around drug development, commercialization, and value creation before investing into BioPharma companies.

This book “Investing into BioPharma Products in the USA—A Reference Guide” has been designed to assist investors to better understand what it takes to (i) develop and commercialize drugs, (ii) spot potential investment opportunities, and (iii) assess potential risks associated with these investment opportunities. We believe that a robust understanding of the methodology required to develop an attractive product value proposition for patients, providers, payers, and policy makers to maximize chances of commercial success is at the heart of value creation for any product. Prudent investors could leverage the information provided in this book to assess the available range of investment opportunities and make informed investment decisions. It’s given that every investment opportunity comes with a certain degree of risk and understanding the nature of risks along the BioPharma value chain and their implications is an imperative for prudent investing.

RxCommercial Research International offers valuable insights to investors to help them understand the intricacies involved in investing into the BioPharma, Medical Devices, and Diagnostics sectors. We hope you find the information and insights in this book useful as you evaluate investment opportunities. We encourage you to invest into BioPharma sector to support the development of next generation products to improve the lives of patients around the world.

If you have any questions on this publication, you could contact us via info@RxCinternational.com